Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
Mayo Clinic Health TAPESTRY: Use of Genomic Sequencing in Clinical Practice (TAPESTRY)
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.,
Jacksonville, Fla.
Tapestry is a Mayo Clinic research study, which includes receiving genetic sequencing data from Helix, up to the full whole exome dataset. The goal of this study is to provide: (i) an immediate interpretation of ancestry/genealogy and several non-disease traits, as well as, clinically actionable variants for an inherited form of high cholesterol called familial hypercholesterolemia (FH), breast and ovarian cancer (HBOC), and Lynch syndrome to each participant; (ii) an additional subset of focused clinically actionable genetic findings, such as, certain types of hereditary cancers, hereditary heart conditions and severe responses to certain medications, will be returned to the provider and to the participant, via the provider, genetic counselor consultation, and/or Mayo Clinic research interpretation; (iii) storing of genomic and phenotypic data for future research analysis.
-
RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors (IGNYTE)
Scottsdale/Phoenix, Ariz.,
Rochester, Minn.
The purpose of this study is to evaluate the dose escalation and expansion of RP1 alone and combined with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary effectiveness.
Closed for Enrollment
-
A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome
Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate the effectiveness and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with Basal Cell Nevus Syndrome (BCNS; Gorlin Syndrome).
-
A Phase II Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma
Scottsdale/Phoenix, Ariz.
The purpose of this study is to estimate the clinical benefit of REGN2810 for patients who have metastatic (in lymph nodes or distant) squamous cell skin cancer or locally advanced squamous cell skin cancer that cannot be removed with surgery.
-
A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients (RegiSONIC)
Scottsdale/Phoenix, Ariz.,
Jacksonville, Fla.
This multi-center, prospective, observational cohort study will evaluate the effectiveness, safety and utilization of treatments in patients with advanced basal cell carcinoma and basal cell carcinoma nevus syndrome. The total study duration is anticipated to be a maximum of 8 years, including 3 years for patient recruitment and 5 years follow-up.
-
R2810-ONC-1620: A Phase 2 Study of Cemiplimab, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Scottsdale/Phoenix, Ariz.
The primary objective is to estimate the overall response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with Cemiplimab as a monotherapy.
.